Slide 1: Agreement to Acquire Trillium Therapeutics
Agreement to Acquire Trillium Therapeutics August 23rd, 2021 Brings Potentially Transformative Foundational Hematology / Oncology Immuno- Therapeutic Agents Breakthroughs that change patients’ lives ® Confidential 1 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our discussions during this conference call will include forward-looking statements and forward-looking information that are subject to substantial risks and uncertainties, many of which are beyond our control, that could cause actual results to diffe
Slide 3: Today's Speakers
Today’s Speakers Andy Schmeltz Chris Boshoff Jeff Settleman Oncology Global President Oncology Chief Development Officer Oncology Chief Scientific Officer Confidential 3 3
Slide 4: Transaction Overview
Transaction Overview Pfizer to gain access to Subject to customary two investigational novel Diversifies Pfizer’s closing conditions Agreement to acquire all immune checkpoint Oncology pipeline with • Structured as a of the outstanding blockers potential to be used in Canadian Plan of shares of Tri
Slide 5: Acquisition aligns with Pfizer's strategic priorities
Acquisition aligns with Pfizer’s strategic priorities Deploy capital to efficiently create meaningful shareholder value Bias towards “bolt-on” deals with potential for mid- to long-term value creation and revenue and earnings growth Strengthen individual therapeutic areas with capabilities and flags
Slide 6: Proposed acquisition strengthens Pfizer's leadership in Oncology
Proposed acquisition strengthens Pfizer’s leadership in Oncology while enhancing our growing Hematology/Oncology portfolio Pfizer Oncology Areas of Focus Breast Cancer Genitourinary Cancer Precision Medicine Hematology Select Inline Select Inline Select Inline Select Inline Select Pipeline Select Pi
Slide 7: An immuno-oncology company developing innovative therapies for the treatment of cancer
An immuno-oncology company developing innovative therapies for the treatment of cancer, focused primarily on hematologic malignancies • Founded in 2004 and based in Cambridge, Massachusetts and Mississauga, Ontario • Developing biologics targeting SIRPα / CD47 axis (“don’t eat me” signal): TTI-622 (
Slide 8: Tumors use the SIRPα / CD47 "don't eat me" signal to evade destruction
Tumors use the SIRPα / CD47 “don’t eat me” signal to evade destruction by the innate immune system • Many hematologic and solid tumors express high levels of CD47 • High CD47 expression correlates with more aggressive disease & poorer clinical outcomes • CD47 delivers an inhibitory “don’t eat me” si
Slide 9: TTI-622 and TTI-621: Two novel investigational CD47-SIRPα blocking agents
TTI-622 and TTI-621: Two novel investigational CD47-SIRPα blocking agents with built-in activating signals • CD47 blockade is not sufficient to trigger macrophage anti-tumor activity; macrophages also need an “eat me” (pro- phagocytic) signal • TTI-622 and TTI-621 not only block CD47 from engaging S
Slide 10: TTI-622 and TTI-621 demonstrate minimal RBC binding
TTI-622 and TTI-621 demonstrate minimal RBC binding • On-target anemia is problematic for anti-CD47-based therapeutics • ‘622 and ‘621 SIRPα Fc fusion proteins demonstrate minimal RBC binding to enable a better therapeutic index: • Reduces risk of anemia • Potentially lowers dosing requirement by av
Slide 11: In ongoing Phase 1 study, TTI-622 has been well tolerated
In ongoing Phase 1 study, TTI-622 has been well tolerated • Minimal anemia • Related Grade 3-4 AEs were rare and limited to transient cytopenias • Most common unrelated AEs were mild constitutional and gastrointestinal symptoms • No MTD identified Based on the data in clinical database as of 12 Apr
Slide 12: Phase 1 monotherapy activity in multiple hematological malignancies
Potential class-leading monotherapy activity in multiple hematological malignancies provides strong basis for future combination strategies PHASE 1 MONOTHERAPY ACTIVITY 622 33% ORR* at doses 0.8-18 mg/kg in R/R lymphomas 18-29% ORR* at up to 2.0 mg/kg in R/R lymphomas 621 Source: Trillium’s’ Data cu
Slide 13: TTI-622 monotherapy activity observed in multiple lymphoid malignancies, with 33% ORR
TTI-622 monotherapy activity observed in multiple lymphoid malignancies, with 33% ORR Response evaluable patients only; Based on the data in clinical database as of 12 Apr 2021; data are subject to change priorto final database lock Source: Trillium’s April 28th R&D Day Presentation – Phase 1 data C
Slide 14: TTI-622 demonstrated durable and ongoing efficacy (Updated July 2021)
TTI-622 demonstrated durable and ongoing efficacy (Updated July 2021) Source: Data as of 26 Jul 2021 (data are subject to change prior to final database lock) – Phase 1 data Updates based on verbal/email communication with sites; corresponding data is not yet entered into the EDC Response evaluable
Slide 15: Deep and durable monotherapy responses in heavily pretreated advanced DLBCL patients
Deep and durable monotherapy responses (still ongoing) are seen in heavily pretreated patients with advanced DLBCL CR in DLBCL @ 0.8 mg/kg dose PR in DLBCL @ 18 mg/kg dose 114 + 28+ Ongoing Based on the data in clinical database as of July 26 2021; data are subject to change prior to final database
Slide 16: This opportunity delivers breakthrough potential and enhances growth prospects
This opportunity delivers breakthrough potential and enhances growth prospects • TTI-622 and TTI-621 are novel, potentially best-in-class SIRPα / CD47 immuno-therapeutics • TTI-622 and TTI-621 are the only known CD47-targeted molecules that have demonstrated Opportunity single agent activity and com
Slide 17: Q&A Session
Q&A Session Pfizer Oncology Snapshot $10.9B 300+ +21% 716,000+ 7+1 2020 Clinical trials Operational revenue Patients served Approved Investigational Global currently underway growth in 2020 in 2020* Revenue …therapies in the Hematology/ Oncology portfolio Oncology Inline portfolio of 24 cancer medic